Pantoprazole Dosing in Children
Pantoprazole is NOT recommended as first-line therapy in children, as it has no FDA pediatric indication and lacks weight-based dosing guidance in official labeling. 1
FDA-Approved Status and Limitations
The FDA label explicitly states "No pediatric indication" for pantoprazole 2. While the drug has been studied in pediatric populations aged 1-16 years for erosive esophagitis (EE) associated with GERD, no appropriate dosage formulation exists for children under 5 years 1. The FDA-approved dosing table lists only "40 mg daily (adult dose)" with oral tablets 2.
Weight-Based Dosing from Clinical Studies
Despite lack of FDA approval, clinical trials have evaluated pantoprazole in children:
For Children 1-5 Years Old:
- 0.6 mg/kg or 1.2 mg/kg once daily were studied 1, 3, 4
- The 1.2 mg/kg dose provided exposure most comparable to adults receiving 40 mg 5, 4
- Practical dosing used: 15 mg for ≤12.5 kg; 20 mg for >12.5 to <25 kg 1
For Children ≥5 Years Old:
- Weight-tiered dosing (not per-kg dosing) is most appropriate:
- 20 mg once daily for 15 kg to <40 kg
- 40 mg once daily for ≥40 kg 1
Critical Dosing Considerations
Use lean body weight (LBW), not total body weight (TBW), for children with obesity. TBW-based dosing results in 50% reduced drug clearance and excessive systemic exposure in obese children 6. LBW-based dosing at 1.2 mg/kg achieves comparable exposures regardless of obesity status 6.
Weight-tiered dosing achieves target exposure in >90% of children regardless of obesity status or CYP2C19 phenotype, making it superior to strict mg/kg dosing 7.
Preferred Alternatives
Consider omeprazole, lansoprazole, or esomeprazole instead, as these have FDA approval for pediatric use starting at age 1 year with established weight-based dosing (0.7-3.3 mg/kg/day) 2. The AAP Pediatrics guideline (2013) provides clear dosing for these alternatives but notably lists pantoprazole as having "no pediatric indication" 2.
Safety Concerns
Pantoprazole was not effective in infants <1 year in placebo-controlled trials 1. In this age group, systemic exposure was 103% higher in preterm infants/neonates and 23% higher in infants 1-11 months compared to adults, with no demonstrated efficacy 1.
Common adverse events in pediatric trials included vomiting, diarrhea, abdominal distension, and electrolyte abnormalities (hypokalaemia, hyponatraemia), with higher rates in children receiving ≥4 days of treatment 8.
Clinical Bottom Line
If pantoprazole must be used despite lack of FDA pediatric indication:
- Ages 5-16 years: Use weight-tiered dosing (20 mg for 15-40 kg; 40 mg for ≥40 kg)
- Ages 1-5 years: Consider 1.2 mg/kg once daily (off-label), but FDA-approved alternatives are strongly preferred
- Infants <1 year: Do not use—no demonstrated efficacy
- Children with obesity: Dose based on lean body weight, not total body weight
- Duration: Treat for 8 weeks before assessing response 1